South Korea
· Delayed Price · Currency is KRW CTCBIO Statistics
Total Valuation
CTCBIO has a market cap or net worth of KRW 185.05 billion. The enterprise value is 206.52 billion.
| Market Cap | 185.05B |
| Enterprise Value | 206.52B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCBIO has 23.91 million shares outstanding. The number of shares has increased by 0.57% in one year.
| Shares Outstanding | 23.91M |
| Shares Change (YoY) | +0.57% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.12% |
| Owned by Institutions (%) | 0.50% |
| Float | 13.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.38 |
| PB Ratio | 2.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.78 |
| EV / Sales | 1.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -56.26 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.21 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | -9.49 |
| Interest Coverage | -2.02 |
Financial Efficiency
Return on equity (ROE) is -17.73% and return on invested capital (ROIC) is -3.18%.
| Return on Equity (ROE) | -17.73% |
| Return on Assets (ROA) | -2.35% |
| Return on Capital (ROIC) | -3.18% |
| Revenue Per Employee | 557.45M |
| Profits Per Employee | -67.03M |
| Employee Count | 241 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.62 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.78% |
| 50-Day Moving Average | 7,278.60 |
| 200-Day Moving Average | 8,256.80 |
| Relative Strength Index (RSI) | 66.36 |
| Average Volume (20 Days) | 138,572 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CTCBIO had revenue of KRW 134.35 billion and -16.15 billion in losses. Loss per share was -673.74.
| Revenue | 134.35B |
| Gross Profit | 45.11B |
| Operating Income | -6.46B |
| Pretax Income | -16.96B |
| Net Income | -16.15B |
| EBITDA | -1.23B |
| EBIT | -6.46B |
| Loss Per Share | -673.74 |
Balance Sheet
The company has 19.59 billion in cash and 34.85 billion in debt, giving a net cash position of -15.26 billion or -638.37 per share.
| Cash & Cash Equivalents | 19.59B |
| Total Debt | 34.85B |
| Net Cash | -15.26B |
| Net Cash Per Share | -638.37 |
| Equity (Book Value) | 79.15B |
| Book Value Per Share | 3,051.15 |
| Working Capital | 14.14B |
Cash Flow
In the last 12 months, operating cash flow was -1.40 billion and capital expenditures -2.27 billion, giving a free cash flow of -3.67 billion.
| Operating Cash Flow | -1.40B |
| Capital Expenditures | -2.27B |
| Free Cash Flow | -3.67B |
| FCF Per Share | -153.54 |
Margins
Gross margin is 33.58%, with operating and profit margins of -4.81% and -12.02%.
| Gross Margin | 33.58% |
| Operating Margin | -4.81% |
| Pretax Margin | -12.62% |
| Profit Margin | -12.02% |
| EBITDA Margin | -0.91% |
| EBIT Margin | -4.81% |
| FCF Margin | -2.73% |
Dividends & Yields
CTCBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.57% |
| Shareholder Yield | -0.57% |
| Earnings Yield | -8.70% |
| FCF Yield | -1.98% |
Stock Splits
The last stock split was on April 22, 2013. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 22, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
CTCBIO has an Altman Z-Score of 2.02. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.02 |
| Piotroski F-Score | n/a |